arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

KIORA PHARMACEUTICALS INC

KPRX

$2.63 ▲ +0.13 (+5.40%) at close

13 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

KIORA PHARMACEUTICALS INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $11.0M

Dividend Yield —

Revenue Growth N/M

Op. Margin None

ROIC -71.1% ↘

FCF / Share $-2.42 ↘

Trailing P/E —

Price / Book 0.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

13-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-10.84M

↓ -401.4% —

FCF / Share Free cash flow per share

$-2.42

↓ -209.5% —

Long-Term Debt Long-term obligations

$278.19K

— —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Revenue Growth YoY (%)	N/M	—	—	—	N/M	-99.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1344%)	62.5% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+682%)	305.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3719%)	-39.1% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-589%)	—	—	—	—
EPS Growth YoY (%)	N/M	N/M	98.4% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	73.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution Caution Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	N/M	N/M	7.9% Fair ↑ Fair Improving Year-over-year change in net income	17.1% Good ↑ Good Improving Year-over-year change in net income	-102.6% Weak ↓ Weak Declining Year-over-year change in net income	-14.0% Weak ↓ Weak Declining Year-over-year change in net income	34.4% Excellent ↑ Excellent Improving Year-over-year change in net income	18.2% Good ↑ Good Improving Year-over-year change in net income	0.9% Caution ↑ Caution Improving Year-over-year change in net income	-59.1% Weak Weak Year-over-year change in net income	-440.6% Weak Weak Year-over-year change in net income	—	—
Revenue CAGR 3Y (%)	—	—	—	—	—	-69.1% Weak Weak Compound annual revenue growth over 3 years	58.9% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—	—
Revenue CAGR 5Y (%)	—	42.9% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Operating Margin (%) (%)	—	28.2% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+88%)	—	—	—	—	—	—	—	—	—	—	—
Effective Tax Rate (%) (%)	10.6% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	36.5% Weak ↑ Weak Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.7% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.8% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.8% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.4% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.8% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	9.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
Profit Margin (%) (%)	—	22.4% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+87%)	—	—	—	—	-264.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2302%)	—	—	—	—	—	—
FCF Margin (%) (%)	—	53.4% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	-303.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—
FCF / Net Income (x)	0.93x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	2.38x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.91x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.15x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.00x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.49x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.63x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Return on Invested Capital (%)	-71.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	11.1% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	-207.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-107.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-180.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-113.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	-122.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	—
Return on Capital (%) (%)	-52.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	12.4% Good ↑ Good Improving Operating profit relative to total assets Optimal: > 10%	-91.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-65.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-93.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-54.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-75.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	-67.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-548%)	14.0% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-7%)	-204.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1465%)	-119.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-894%)	-177.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1285%)	-115.6% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-871%)	-107.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-814%)	-121.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-907%)	—	—	-137.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1019%)	3.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-78%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Debt to Equity (x)	—	—	—	—	—	0.04x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-93%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—	—	—	—
Interest Coverage (x)	—	—	—	-1431.51x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-2472.99x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-1961.96x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	-10427.60x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—
Net Debt (USD)	$-8.70M	$-3.79M	$-2.45M	$-5.96M	$-7.85M	$-907.49K	$-3.78M	$-8.00M	$-7.81M	$-3.64M	$-8.39M	$-167.00K	$-501.17K
Debt / EBITDA (x)	—	—	—	—	—	-0.03x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Revenue per Share (USD)	$0.00	$4.14	$0.00	—	$0.00	$8.55	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-2.60	$0.93	$-24.25	$-1.50K	$-5.74K	$-5.74K	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-2.42	$2.21	$-17.76	—	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$4.29	$8.58	$7.14	$21.43	$2.36K	$4.09K	$5.27K	—	$-6.04K	$-1.76K	—	—	—
Tangible Book Value per Share (USD)	$3.74	$6.36	$-3.16	$1.25	$135.42	$-3.63K	$767.91	$4.02K	—	$-1.76K	—	—	—
Basic Weighted Avg Shares (shares)	4.17M	3.87M	538,007	9,032	2,849	1,411	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Working Capital (USD)	$18.12M	$23.70M	$3.10M	$4.41M	$7.38M	$-46.11K	$2.91M	$4.61M	$-6.37M	$-3.15M	$6.03M	$-4.81M	—
LT Debt (USD)	—	—	—	—	—	$278.19K	$0.00	—	—	—	—	—	—
Total Equity (USD)	$16.13M	$25.76M	$6.11M	$11.41M	$9.22M	$7.00M	$6.62M	$8.94M	$-1.93M	$-329.42K	$6.09M	$-46.81M	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$16.02M	$0.00	—	$0.00	$12.06K	$2.69M	$1.65M	$407.52K	$669.26K	$0.00	—	—
Depreciation Expense (USD)	$24.80K	$19.20K	$51.80K	$41.61K	$45.30K	$33.40K	$51.67K	$38.48K	$19.29K	$5.18K	$1.26K	$1.72K	—
Net Income, GAAP (USD)	$-10.84M	$3.59M	$-12.51M	$-13.58M	$-16.39M	$-8.09M	$-7.10M	$-10.81M	$-13.22M	$-13.34M	$-8.39M	$-1.55M	—
Operating Cash Flow (USD)	$-9.96M	$8.56M	$-9.56M	$-10.43M	$-10.89M	$-7.32M	$-8.15M	$-10.84M	$-6.47M	$-8.41M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 50 quarters

KIORA PHARMACEUTICALS INC

Analytical Summary

13-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare KPRX with peers